Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stake Cut by Vontobel Holding Ltd.

Vontobel Holding Ltd. cut its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 13.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,264 shares of the biopharmaceutical company’s stock after selling 1,149 shares during the quarter. Vontobel Holding Ltd.’s holdings in Alnylam Pharmaceuticals were worth $1,998,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of ALNY. Vanguard Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 0.4% during the first quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company’s stock worth $1,792,542,000 after purchasing an additional 50,366 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Alnylam Pharmaceuticals by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock worth $550,837,000 after buying an additional 201,784 shares in the last quarter. Capital International Investors boosted its stake in shares of Alnylam Pharmaceuticals by 1.8% during the 1st quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock valued at $545,674,000 after buying an additional 64,560 shares during the period. Capital Research Global Investors grew its holdings in shares of Alnylam Pharmaceuticals by 7.3% during the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after acquiring an additional 214,908 shares in the last quarter. Finally, Bellevue Group AG increased its stake in shares of Alnylam Pharmaceuticals by 3.7% in the first quarter. Bellevue Group AG now owns 918,284 shares of the biopharmaceutical company’s stock worth $137,238,000 after acquiring an additional 32,966 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of the business’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the sale, the director now owns 136 shares of the company’s stock, valued at $35,632. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,148 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares in the company, valued at $19,829,070. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Dennis A. Ausiello sold 20,250 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the sale, the director now owns 136 shares in the company, valued at approximately $35,632. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,398 shares of company stock valued at $13,595,460 over the last ninety days. 1.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ALNY. BMO Capital Markets restated an “outperform” rating and issued a $234.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, June 24th. JPMorgan Chase & Co. boosted their price target on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a research note on Monday, August 26th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. Scotiabank assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday. They issued a “sector outperform” rating and a $305.00 target price for the company. Finally, Bank of America raised their price target on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a report on Monday, October 14th. Six research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $286.82.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $295.93 on Friday. The firm’s 50-day moving average is $271.82 and its 200-day moving average is $216.59. The company has a market cap of $37.43 billion, a price-to-earnings ratio of -110.42 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. During the same quarter in the prior year, the firm earned ($2.21) earnings per share. The company’s revenue was up 107.0% on a year-over-year basis. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.